&
By the year 2000 it is estimated that more than 20 million people worldwide will be infected with HIV. Despite many research-related problems, pharmaceutical companies and academic researchers are channelling their efforts into developing new anti-HIV compounds. As outlined by presentations at AIMECS 95 [ AFMC International Medicinal Chemistry Symposium; Tokyo, Japan; September 1995 ] researchers are concentrating on 2 key enzymes in the life-cycle of HIV, namely reverse transcriptase (RT) and HIV protease.
Rights and permissions
About this article
Cite this article
Figgitt, D. Progress with enzyme inhibitors for treating HIV infection. Inpharma Wkly. 1007, 9–10 (1995). https://doi.org/10.2165/00128413-199510070-00021
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199510070-00021